CA3066084C - Methodes de traitement de la fibrose kystique - Google Patents

Methodes de traitement de la fibrose kystique

Info

Publication number
CA3066084C
CA3066084C CA3066084A CA3066084A CA3066084C CA 3066084 C CA3066084 C CA 3066084C CA 3066084 A CA3066084 A CA 3066084A CA 3066084 A CA3066084 A CA 3066084A CA 3066084 C CA3066084 C CA 3066084C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salts
chosen
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3066084A
Other languages
English (en)
Other versions
CA3066084A1 (fr
Inventor
Eric L. Haseltine
Samuel Moskowitz
Sarah Robertson
David Waltz
Weichao George Chen
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority claimed from PCT/US2018/036610 external-priority patent/WO2018227049A1/fr
Publication of CA3066084A1 publication Critical patent/CA3066084A1/fr
Application granted granted Critical
Publication of CA3066084C publication Critical patent/CA3066084C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne un composé I de formule (formule), un sel pharmaceutiquement acceptable du composé I, des compositions pharmaceutiques contenant au moins un composé I et des procédés de traitement de la fibrose kystique comprenant l'administration d'au moins un composé I, des compositions pharmaceutiques contenant un sel pharmaceutiquement acceptable d'au moins un composé I et des méthodes de traitement de la fibrose kystique comprenant l'administration d'un sel pharmaceutiquement acceptable d'au moins un composé I.
CA3066084A 2017-06-08 2018-06-08 Methodes de traitement de la fibrose kystique Active CA3066084C (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762517049P 2017-06-08 2017-06-08
US62/517,049 2017-06-08
US201762533381P 2017-07-17 2017-07-17
US62/533,381 2017-07-17
US201762562044P 2017-09-22 2017-09-22
US62/562,044 2017-09-22
US201862623757P 2018-01-30 2018-01-30
US62/623,757 2018-01-30
US201862633021P 2018-02-20 2018-02-20
US62/633,021 2018-02-20
US201862649266P 2018-03-28 2018-03-28
US62/649,266 2018-03-28
PCT/US2018/036610 WO2018227049A1 (fr) 2017-06-08 2018-06-08 Méthodes de traitement de la fibrose kystique

Publications (2)

Publication Number Publication Date
CA3066084A1 CA3066084A1 (fr) 2018-12-13
CA3066084C true CA3066084C (fr) 2025-10-07

Family

ID=

Similar Documents

Publication Publication Date Title
AU2018279646B2 (en) Methods of treatment for cystic fibrosis
US12350262B2 (en) Methods of treatment for cystic fibrosis
EP4218754B1 (fr) Vanzacaftor pour le traitement de la mucoviscidose
EP2231671B1 (fr) Modulateurs de régulateur de conductance transmembranaire de fibrose cystique
JP6746569B2 (ja) 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
US20210009560A1 (en) Crystalline forms of modulators of cftr
US20200171015A1 (en) Methods of treatment for cystic fibrosis
CA3066084C (fr) Methodes de traitement de la fibrose kystique
EA041854B1 (ru) Способы лечения муковисцидоза
EA041961B1 (ru) Способы лечения муковисцидоза
HK40096538A (en) Methods of treatment for cystic fibrosis
HK40060445A (en) Methods of treatment for cystic fibrosis
HK40060445B (en) Methods of treatment for cystic fibrosis
BR112019025801B1 (pt) Uso de pelo menos um composto selecionado a partir do composto i e composição farmacêutica